| dc.creator |
ERZURUMLU, Yalçın |
|
| dc.creator |
Dogan, Hatice Kubra |
|
| dc.creator |
ÇATAKLI, Deniz |
|
| dc.date |
2023-01-01T00:00:00Z |
|
| dc.date.accessioned |
2025-02-25T10:32:21Z |
|
| dc.date.available |
2025-02-25T10:32:21Z |
|
| dc.identifier |
77534192-13ba-4db0-b79f-6583e17460d2 |
|
| dc.identifier |
10.33483/jfpau.1232868 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/77534192-13ba-4db0-b79f-6583e17460d2/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/100211 |
|
| dc.description |
Objective: The aim of this study was to investigate the possible synergistic effect of curcumin on the anticancer features of gemcitabine on prostate cancer cells. Material and Method: The human prostate adenocarcinoma cell line LNCaP was used in the studies. The effect of the co-administration of gemcitabine and curcumin on the viability of LNCaP cells was investigated by the WST-1 assay. Autophagy, ubiquitin-proteasome system (UPS), unfolded protein response (UPR) and cell death-associated proteins, androgenic signaling, proto-oncogenic, angiogenic and epithelial-mesenchymal transition (EMT) associated protein levels were investigated by immunoblotting studies. Result and Discussion: Our results showed that curcumin potentiated the anticancer effects of gemcitabine on LNCaP cells. Co-administration of curcumin and gemcitabine strengthened the suppressive effect of gemcitabine on cell viability. Moreover, co-administration modulated the autophagy, more strongly stimulated UPS and UPR, suppressed androgenic signaling, led to the activation of cell death-related poly [ADP-ribose] polymerase 1 (PARP-1) and caspase-3 and strongly suppressed the expression levels of proto-oncogenic c-Myc and angiogenic vascular endothelial growth factor-A (VEGF-A). In addition, it was determined that co-administration negatively regulated EMT by stimulating E-cadherin expression and suppressing N-cadherin level. These results suggest that the combined usage of gemcitabine and curcumin may offer a potent therapeutic approach to prostate cancer by enhancing the anticancer effects of gemcitabine. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.title |
CURCUMIN, THE BIOACTIVE COMPOUND OF TURMERIC, MAY IMPROVE THE ANTI-MALIGNANT PROPERTY OF GEMCITABINE IN PROSTATE CANCER CELLS ZERDEÇALIN BİYOAKTİF BİLEŞİĞİ KURKUMİN, GEMSİTABİNİN PROSTAT KANSERİ HÜCRELERİNDEKİ ANTİ-MALİGNANT ÖZELLİĞİNİ GELİŞTİREBİLİR |
|
| dc.type |
info:eu-repo/semantics/article |
|